School of Medicine

• 

  People

  • Administrative Positions

    • Andolsek, Kathryn Marijoan, Assistant Dean, Premedical Education in the School of Medicine
    • Andrews, Nancy Catherine, Dean Emerita of the School of Medicine
    • Brown, Ann Julia, Vice Dean for Faculty
    • Buckley, Edward George, Vice Dean for Education
    • Buckley, Edward George, Vice Chancellor for Duke-National University Singapore Affairs
    • Chikaraishi, Dona M., Associate Dean for Biomedical Grad Educ and Leadership
    • Corless, Joseph M., Vice Dean Emeritus for Faculty and Academic Affairs
    • Dewhirst, Mark Wesley, Associate Dean for Faculty Mentoring
    • Drucker, Robert Patrick, Associate Dean for Medical Education
    • Gbadegesin, Rasheed Adebayo, Associate Dean for Physician-Scientist Development
    • Gbadegesin, Rasheed Adebayo, Director of the Office of Physician-Science Development in the School of Medicine
    • Klotman, Mary E, Dean, School of Medicine
    • Kuhn, Catherine, Associate Dean for Graduate Medical Education
    • Levin, Edward Daniel, Director, Integrated Toxicology Program
    • Lodge, Jennifer Katherine, Vice President for Research and Innovation
    • Nicchitta, Christopher Vincent, Associate Dean of Research Training
    • Pappas, Theodore N., Vice Dean, Medical Affairs
    • Pencina, Michael J, Vice Dean, Data Science and Information Technology
    • Pencina, Michael J, Director of Duke AI Health
    • Perakslis, Eric, Chief Research Technology Strategist
    • Sheline, Barbara LaTowsky, Assistant Dean for Primary Care
    • Snyderman, Ralph, Chancellor Emeritus of Duke University
    • Swamy, Geeta Krishna, Vice Dean and Associate Vice Provost for Scientific Integrity
    • Tcheng, James Enlou, Assistant Dean for Academic Appointments
    • Thomas, Kevin Lindsey, Vice Dean for Diversity, Equity and Inclusion
    • Washington, A. Eugene, Chancellor for Health Affairs, Duke University and President and CEO of Duke University Health System
    • Wigfall, Delbert Raye, Associate Dean for Medical Education

  • Secondary Appointments

    • Akwari, Anne Micheaux, Medical Center Instructor in the School of Medicine

  • Non-Faculty Positions

    • Brouwer, Rebecca, Dir, Research Initiatives
    • Holtschneider, Mary, Nursing Program Manager
    • Redmond, Rebecca, Dir, Edi Assessment & Research
    • Sendak, Mark, Consultant, IT
    • Snyder, Denise, Assoc Dean, Clinical Research
    • Stroo, Marissa, Dir, Clinical Res Educ Training and Ops
    • Von Isenburg, Megan, Prof Library Staff
    • Woolley, Donald, Higher Education Analyst I

  • Affiliate Positions

    • Vaz, Alex, Affiliate

  • Students

    • Bassil, Christopher, Student
    • Behrer, Christopher, Student
    • Cerda-Smith, Christian, Student
    • Liu, Winston, Student
    • Petrone, Brianna, Student
    • Stilwell, Laura, Student
• 

  Administers Grant

  • 18-0006 Mod 6 (EA)
  • A 6-Week, Randomized, Multicenter, Double-Blind, Parallel, Flexed- and Fixed-dose Study of MG01CI (Metadoxine Extended-Release) 700 Mg and 1400 Mg Compared with Placebo in Adults and Adolescents with Fragile X Syndrome
  • A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety
  • A Multicenter, Open-Label Study Evaluating the Long-Term Safety, and Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventative Treatment of Episodic Migraine in Pe
  • A Multicenter, Randomized, DoubleBlind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pedia
  • A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3200327 in Subjects with Active Sjögren¿s Syndrome
  • A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients with Neutrophilic Skin Diseases
  • A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)
  • A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and
  • A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of MEDI6012 in Subjects with Stable Coronary Artery Disease
  • A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects with X-Linked Hypophosphatemia (XLH)
  • A Phase 3, Placebo Controlled, Randomized, Observer-Blinded Study to Evaluate the Efficacy, Safety, and Tolerability of a Clostridium Difficile Vaccine in Adults 50 Years of Age and Older
  • A Phase 3, Randomized, Multicenter, Multinational, Double-Blinded Study Comparing the Efficacy and Safety of Repeated Bi-Weekly Infusions ff neoGAA (GZ402666) and Alglucosidase Alfa in Treatment Naive Patients With Late Onset Pompe Disease"
  • A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efg
  • A Phase III Randomized, Observer-Blind, Placebo-Controlled Study to Demonstrate the Efficicay of Respiratory Syncytical Virus (RSV) Recombinant F Nanoparticale Vaccine in Prevention of Acute, Symptomatic RSV-Associated Respiratory Disease, and Acute
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of KRN23 in Adult Patients with X-linked Hypophosphatemia (XLH)¿
  • A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety and Efficacy of LGD-6972 in Patients with Type 2 Diabetes Mellitus
  • A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication
  • A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis
  • A randomized, double-blind, placebo-controlled, parallel group 26-week dose-investigating study to explore the pharmacokinetics, pharmacodynamic effects, efficacy, safety and tolerability of RO5186582 in children with Down syndrome aged 6-11 years.
  • AHEC Primary Care / ORPCE FY17
  • AHEC Primary Care / ORPCE FY18
  • AHEC Primary Care Initiative / ORPCE FY16
  • AHEC COMPOSITE FY20
  • AHEC COMPOSITE FY22
  • AHEC Composite FY16
  • AHEC Composite FY17
  • AHEC Composite FY18
  • AHEC Composite FY19
  • AHEC Health Careers & Work Force Diversity FY15
  • AHEC Health Careers & Workforce Diversity FY16
  • AHEC Health Careers / Model State-Supported AHEC Grant FY20
  • AHEC Health Careers / Point of Service Maint & Enhancement FY18
  • AHEC Health Careers / Point of Service Maint & Enhancement FY19
  • AHEC Health Careers / Point of Service Maintenance & Enhancement FY17
  • AHEC MSSAG / HEALTH CAREERS FY21
  • AHEC MSSAG / HEALTH CAREERS FY22
  • AHEC Mental Health FY16
  • AHEC Mental Health FY17
  • AHEC Mental Health FY18
  • AHEC Operations Composite FY15
  • AHEC RESIDENCY SUPPORT FY21
  • AHEC RESIDENCY SUPPORT FY22
  • AHEC Residency Support FY15
  • AHEC Residency Support FY16
  • AHEC Residency Support FY17
  • AHEC Residency Support FY18
  • AHEC Residency Support FY19
  • AHEC Residency Support FY20
  • Affecting Culture Change: Building Unit-Level Infrastructure to Mitigate Research Integrity Risk
  • An Activatable Nanoparticle Probe for Molecular Imaging of Protease Activity by Dual Energy CT
  • An Exploratory Phase II Study to Determine the Safety, Tolerability, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults with DSM-5 Intermittent Explosive Disorder (IED)
  • An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults with X-Linked Hypophosphatemia (XLH)
  • Animal Housing And Maintenance : Rfp 273-94-P-0004
  • Asfaw - IPA
  • Assessing Use of Acoustic Radiation Force to Noninvasively Measure Liver Pressure
  • B43541003 Type 1 Diabetes Phase I Study
  • BMS CV202-010-0055
  • Biological Role And Mechanism Of Action Of Nef
  • Biological Roles And Mechanism Of Action Of Nef
  • Building Opportunities and Overtures in Science and Technology
  • Bundled Testing and Patient navigation
  • COMBINE - ARLG 2.0 - DEPRU Site Budget (Yr8 of ARLG/Yr1 of ARLG 2.0)
  • Caldwell IPA
  • Cannady--Atlanta IPA
  • Cardiac Filling Pressure Estimation with a Non-Invasive Device (Pufferfish)
  • Characterization of the role of Din7 in mitochondrial DNA replication and genome integrity in the yeast Saccharomyces cerevisiae
  • Cloning Of Hereditary Hemorrhagic Telangiectasia Gene
  • Cloning The Hereditary Hemorrhagic Telangiectasia Gene
  • Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
  • Creation of a Secured IRB Protocol Management System
  • Deep learning for prognostication in breast cancer
  • Defining the cellular target of radiotherapy in primary mouse models of cancer
  • Digital Device Library
  • Display Memory Mutant Repressors Of Hiv Replication
  • Dissecting the role of ATRX in soft tissue sarcoma development and radiation response
  • Dissecting the roles of HIF-1a and HIF-2a in tumor response to radiation therapy
  • Diversity Of Tgf Beta Receptor Mutations In Hht Syndrome
  • Drake-Atlanta IPA
  • Duke BioCoRE: Increasing Diversity through Student and Faculty Engagement
  • DukeMed Activated
  • EPCTU - Task Area A - Admin and Overall
  • Endothelial Cell Lineage Studies in Cerebral Cavernous Malformations
  • Enhancing Duke University's Animal Resources
  • Enhancing a culture of inclusiveness and support for minority scientists and faculty through the Duke BioCoRE Program
  • Enhancing dendritic cell migration to drive potent anti-tumor immune responses
  • Evaluation of GIMate Handheld Hydrogen Breath Monitor for Diagnosis of Lactose Malabsorption
  • Expansion of Animal Resources for Large Animals (Vivarium Expansion project)
  • Fibroblast Growth Factor Homologous Factor Modulation and Effect on Cardiac Ion Channel Trafficking
  • First-in-human (FIH) Safety and Dose Ranging Study of TT-034 in Patients with Chronic Hepatitis C (CHC) Infection
  • First-in-human SAD & MAD trials for MW151, a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation
  • Fund to Retain Clinical Scientists at Duke
  • GCRC - Uterine Longitudinal Leiomyoma Intervention Study
  • GS-US-326-1100 Dr. Onken Study
  • Gcrc-Cap-Michael Morse
  • General Clinical Research Center
  • General Clinical Research Center
  • Gertrude B. Elion Mentored Medical Student Award
  • Gertrude B. Elion Mentored Medical Student Award
  • Gertrude B. Elion Mentored Medical Student Award
  • Gertrude Elion Mentored Medical Research Award
  • Gertude B. Elion Mentored Medical Research Award
  • Get Data @ Duke
  • Glucose Metabolism and p53 in Leukemia
  • HIV Early Intervention Testing
  • Healthy Volunteer Study of CSF fluid and Oral Bioavailability of RR-HNK
  • Housing Opportunities for Persons with AIDS
  • Housing Opportunities for Persons with AIDS
  • Humoral And Cellular Mediators Of Inflammation
  • IPA, Thomas Skeuse
  • IPA--Katie Clikscales
  • IPA-Connor Drake
  • Immune Correlates of Protection Against Congenital Cytomegalovirus Transmission in an HIV-Infected Mother-Infant Cohort
  • Immunosuppressant Targets In Cryptococcus Neoformans
  • Improving the Bryan Vivarium in Support of the Rodent Imaging Core
  • Integrated Human Research Subjects Protection Project
  • Interneuron Synapses: In Vivo Chemicogenetic Proteomics to Discover Developmental Brain Disorder Etiologies
  • Investigating the Metabolic Reprogramming of Ovarian Tumors During Omental Metastasis
  • MIP1404-1301
  • MYK-461-001 Hypertrophic Cardiomyopathy and Healthy Volunteers
  • MYK-461-019 (EMBARK)
  • Mechanism Of Action Of The Hiv-1 Rev Gene Product
  • Medical Scientist Training Program
  • Medical Scientist Training Program
  • NBME OSCE for Clinical Reasoning Creative Community
  • Novel Antifungal Drug Targets In Cryptococcus Neoformans
  • Novel Ondansetron Formulation for Combination Treatment of Psychostimulant Abuse
  • P1CTU Protocol Development for 17-0033 (Base)
  • P1CTU_Task Order 16_Protocol Implementation (Mod 3)
  • PHASE 1 CLINICAL TRIAL UNITS FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES ADMINISTRATIVE AND OVERALL CLINICAL OPERATIONS SUPPORT AND CONCEPT DEVELOPMENT TASK AREA A TASK ORDER.
  • Phase 2 Study of Efficacy, Safety and Tolerability of R05186582 in Adults with Adolescents with Down Syndrome (Clematis)
  • Phase 3 BMN 701 in rhGAA Exposed Subjects with Late-Onset Pompe Disease
  • Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized
  • Phase I Open Label Study to Determine the Pharmacokinetics, Pharmacodynamics, and Safety of IV Ganaxolone in Healthy Adults
  • Phase I Single Ascending Dose and Multiple Ascending Dose Study of 2R,6R-Hydroxynorketamine
  • Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects.
  • Physician Scientist Development Program
  • Preclinical Development of Novel HSP90 Inhibitors for the Prevention and Treatment of Chikungunya Virus Infections
  • Program to Support Student Development and Diversity in Duke Biosciences
  • Protective role of dectin-1 signaling in an animal model of Multiple Sclerosis
  • RTOP 18-0006 Base / Protocol Development
  • RTOP 18-0006 Option 1 / Protocol Implementation
  • RTOP 18-0006 Option 1 / Protocol Implementation
  • RTOP 18-0006 Option 1 Mod 5
  • Role of hedgehog signaling in tumor-associated macrophage polarization
  • Ryan White Part B Region 7 Network of Care
  • Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects
  • Same
  • Same
  • Same
  • Same
  • Sanofi NeoGAA
  • Save a Life Public Education Event
  • Scholarships For Students Of Exceptional Financial Need
  • School of Medicine 2017 Biddle
  • School of Medicine 2020 Biddle
  • School of Medicine 2021 Biddle
  • School of Medicine 2022 Biddle
  • Scientific Outreach and Community Engagement by Diverse Scientists in the Duke University Office Biomedical Graduate Diversity
  • Structural Determination of Novel GPCR Signaling Complexes that Mediate Sustained G Protein Signaling
  • Studying Anticoagulant Synergy of Factor Xa Aptamer and Catalytic Site Inhibitors
  • TASK AREA A, TASK ORDER FY.2018.A1.0095 Task Area A
  • TDE Pickett Road Infrastructure
  • Targeting EGFRvIII in Brain Tumors with Bispecific Antibodies
  • The Follow Up Study Regarding the Safety and Efficacy of TT-034, a Genetically-Modified Adeno-Associated Virus Designed to Target Hepatitis C in a Study Under Protocol B2801001.
  • The Genetics Of Hereditary Hemorrhagic Telangiectasia
  • To assess the safety and tolerability of single agent RP1 in selected organ transplant recipients
  • Trans-Dominant Mutant Repressors Of Hiv-1 Replication
  • VLZ-MD-21
  • What Matters in Mentoring: Effect of Mentor Cultural Awareness on Mentee Outcomes R01-GM094573 (Pls: Byars-Winston, Pfund)
  • same

• Sub-Organizations

Add data to my Website